A phase II trial of docetaxel (D), estramustine (E) and thalidomide (T) in patients with metastatic androgen-independent prostate cancer (AIPC)

@inproceedings{Retter2005API,
  title={A phase II trial of docetaxel (D), estramustine (E) and thalidomide (T) in patients with metastatic androgen-independent prostate cancer (AIPC)},
  author={Avi S. Retter and Philip M. Arlen and James L. Gulley and Lea L Latham and Seth M Steinberg and Clara C. Chen and Elizabeth Tyler Jones and Alisa Trout and William Douglas Figg and William L. Dahut},
  year={2005}
}
4764 Background: We recently published the results of a randomized phase II trial of D+T vs. D alone. With a median potential follow-up of 46.7 mo., the median OS of D+T was 25.9 mo. and 14.7 mo. w...